Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.32

-1.2%

1:55 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (17137)	6/19/2005 6:51:50 PM
From: Biomaven	Read Replies (1) of 52153

I guess what the writer was getting at is that race is not a great proxy for the genetic predisposition to respond to a drug. It's a fair proxy in this case - that's why the drug worked in African Americans but not in Caucasians. But clearly it would have been preferable to have identified the actual genes at issue and come up with a test for identifying them. Preferable, but not economically feasible in this case, at least not in a reasonable amount of time. A few years ago the NEJM had an article claiming that race had no place at all in the practice of medicine. This ultra-PC view flies in the face of the facts - good doctors treat patients of different races differently for certain conditions - hypertension among them. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next